UBS keeps USD 500.00 target for Intuitive Surgical stock

Published on 10/15/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue is estimated at USD 2.91 billion for October 20. Intuitive Surgical stock costs EUR 377.00, 0.17 percent above its Xetra close.

Analyst view and earnings date

UBS maintained its Buy rating and USD 500.00 target on October 13, 2026.
Second-quarter revenue reached USD 2.89 billion, up 18.40 percent year over year.
Intuitive Surgical stock trades at EUR 377.00 at 11:09 a.m. CEST at Lang & Schwarz on October 15, 2026, 0.17 percent above the Xetra close of October 14, 2026.

Schwarzweiß-Reportagefoto eines Chirurgen an der Konsole während einer robotergestützten Operation — Dokumentarische Schwarzweiß-Reportage aus dem OP-Saal illustriert Intuitive Surgical Inc. (US46120E6023) und den Arbeitsalltag der Chirurgie-Robotik, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) was trading at EUR 377.00 at Lang & Schwarz on October 15, 2026, at 11:09 a.m. CEST, 0.17 percent above the Xetra close of October 14, 2026 at EUR 376.35. The latest analyst signal came from UBS, which maintained a Buy rating and a USD 500.00 price target on October 13, 2026, ahead of the company's third-quarter report.

According to Investing.com, UBS said procedure-volume concerns appeared overly cautious and kept its USD 500.00 target. The report also cited a possible 4 percent headwind from the Extended Use Program in 2027, giving investors a specific counter-factor before the results.

What does October 20 bring?

Intuitive Surgical is scheduled to report third-quarter results on October 20, 2026. The investor-relations calendar identifies the earnings conference call for that date, while TradingView cites a consensus revenue estimate of USD 2.91 billion and anticipated earnings per share of USD 2.65 for the quarter.

The earnings setup follows a strong second quarter. MarketBeat reported quarterly revenue of USD 2.89 billion for the period ended June 30, 2026, up 18.40 percent from the prior-year quarter. Earnings per share reached USD 2.80 against a USD 2.48 consensus estimate, a USD 0.32 difference.

Three milestones shape the setup

On July 16, 2026, Intuitive Surgical reported second-quarter revenue of USD 2.89 billion and earnings per share of USD 2.80, according to MarketBeat. On September 8, 2026, Intuitive highlighted a meta-analysis covering 13 benign conditions in its investor-relations news releases. On October 20, 2026, the company is due to publish third-quarter results, with USD 2.91 billion as the cited revenue estimate.

Company profile and trading view

Intuitive Surgical develops robotic-assisted systems for minimally invasive surgery, led by the da Vinci platform. Its second-quarter operating margin was 34 percent on revenue of USD 2.8923 billion, while operating cash flow reached USD 1.0610 billion for the same period.

The current euro quotation remains close to the previous Xetra session's level rather than signaling a large daily repricing. For investors, the October 20 report is the next measurable test of whether the projected USD 2.91 billion in revenue can extend the company's 18.40 percent second-quarter growth rate.

Trading perspective before results

Intuitive Surgical was trading at EUR 377.00 at Lang & Schwarz on October 15, 2026, at 11:09 a.m. CEST, 0.17 percent above the Xetra close of October 14, 2026 at EUR 376.35. The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.